3 Bio-Pharmaceuticals You Can’t Ignore: Arena Pharmaceuticals, Inc. (ARNA), VIVUS Inc. (VVUS)

Page 1 of 2

The last year has been a stellar one for the biotechnology industry. The industry has easily outperformed the market, with all of its indices, including the Amex Biotechnology Index ETF (FBT), the SPDR S&P Biotech ETF (XBI) and iShares NASDAQ Biotechnology Index (IBB), giving returns of more than 20%. The entire industry is heavily dependent for growth on the approvals of the Food and Drug Administration (FDA). According to research by Bloomberg, this year the authority approved the most number of drug candidates in the last fifteen years. The FDA usually approves around 20-25 drugs every year, but this year an exceptional 39 drugs received the FDA nod.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

A number of micro/small-cap bio-pharmaceutical companies have benefited from FDA approvals in the last couple of years, and amongst them are Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amarin Corporation plc (ADR) (NASDAQ:AMRN) and VIVUS, Inc. (NASDAQ:VVUS). These companies have since seen depreciating stock prices due to their inability to convert promise into actual fundamental value. Despite investor backlash, I believe these stocks are worth following and still hold value for investors.

Amarin

Amongst the 3 stocks under discussion today, Amarin is the safest and surest bet. The company has received FDA approval for its Triglyceride lowering drug Vascepa, but is still waiting for a decision on its NCE status. This decision has been the primary hindrance to a much anticipated acquisition of the company and has forced the company management to commercialize Vascepa. Amarin looks to upset GlaxoSmithKline’s Lovaza, which generates sales of approximately a billion dollars every year. What makes Vascepa exciting is the fact that unlike Lovaza, Vascepa also decreases LDL levels. The increase in LDL has been one of the primary reason physicians have been somewhat reluctant to prescribe Lovaza. With this restriction removed, the sales potential of Vascepa can be huge.

Vivus

The large number of FDA approvals also included two obesity control drugs: Qsymia and Belviq. Qsymia has been approved for chronic weight management in addition to reduced calorie diet and exercise. The initial sales data for Qsymia has not been good, but recent reports show that Qsymia has started to gain some momentum. Company disclosures show that Qsymia sales have shown a growth of 68%, and there is a strong expectation that this growth might continue.

Recent research also indicates that use of Qsymia leads to improvements in blood pressure, triglycerides, and cholesterol of obese patients suffering from these issues. This can be another incentive for doctors who have been so far hesitant to prescribe Qsymia due to its after-effects. Despite these setbacks, there is little doubt that Vivus still has a lot of potential, especially considering the obesity epidemic in the United States.

Page 1 of 2

Dividend Stock Alert - Billionaire Robbins' Top Dividend Idea With 70% Upside Potential

Get Paid 3.5% Per Year While Waiting For The Stock Appreciate 70%

Larry Robbins' Glenview Capital Opportunity Fund returned 101.7% in 2013 and Robbins personally made $750 million. The same fund returned 25.3% in 2014. In this FREE REPORT we will share Robbins' top dividend idea that yields 3.5% and has been increasing its dividends for 39 consecutive years. Robbins thinks the stock has the potential to appreciate 70%.

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!